Revelation Biosciences, Inc. (REVB)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.05 USD
+0.02
(1.942%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.03 -0.02 (-0.020%) ⇩ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:18 a.m. EDT
The investment case for this biotechnology firm is effectively nullified by a catastrophic multi-year price collapse. Despite a 'strong buy' analyst recommendation and a lofty price target, the market has punished the stock relentlessly, with four consecutive years of negative annual returns and a total loss of nearly 100% over the trailing four-year window. This structural deterioration suggests the business fundamentals are failing to generate value, rendering any valuation metrics like the low P/B ratio misleading rather than attractive. The recent technicals show a fragile consolidation near the lower end of the yearly range, but the overwhelming downward trend and lack of any recovery signal make a short-term entry highly speculative. Furthermore, there is no dividend income to offset the capital destruction, leaving investors exposed to pure equity risk in a company that has demonstrated an inability to sustain its share price over time. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.053774 |
| MSTL | 0.063467 |
| AutoARIMA | 0.067948 |
| AutoETS | 0.068213 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.75 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.082 |
| Excess Kurtosis | -0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.35 |
| Market Cap | 4,182,586 |
| Trailing P/E | 0.04 |
| Forward P/E | -0.36 |
| Beta | -0.17 |
| Website | https://www.revbiosciences.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.90462965 |
| Address1 | 4,660 La Jolla Village Drive |
| Address2 | Suite 100 |
| All Time High | 2,276,064.0 |
| All Time Low | 0.875 |
| Ask | 1.3 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 67,560 |
| Average Daily Volume3 Month | 46,451 |
| Average Volume | 46,451 |
| Average Volume10Days | 67,560 |
| Beta | -0.169 |
| Bid | 0.756 |
| Bid Size | 2 |
| Book Value | 2.576 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.05 |
| Current Ratio | 6.214 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.06 |
| Day Low | 1.0001 |
| Debt To Equity | 7.35 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -11,241,206 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.584 |
| Enterprise Value | -6,560,289 |
| Eps Current Year | -5.185 |
| Eps Forward | -2.89 |
| Eps Trailing Twelve Months | 27.03 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.05984 |
| Fifty Day Average Change | -0.009840012 |
| Fifty Day Average Change Percent | -0.009284431 |
| Fifty Two Week Change Percent | -90.46297 |
| Fifty Two Week High | 11.6 |
| Fifty Two Week High Change | -10.55 |
| Fifty Two Week High Change Percent | -0.9094827 |
| Fifty Two Week Low | 0.875 |
| Fifty Two Week Low Change | 0.17499995 |
| Fifty Two Week Low Change Percent | 0.19999994 |
| Fifty Two Week Range | 0.875 - 11.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,605,623,400,000 |
| Float Shares | 3,046,397 |
| Forward Eps | -2.89 |
| Forward P E | -0.36332178 |
| Free Cashflow | -5,777,208 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Fullday Change | 0.02 |
| Fullday Change Percent | 1.94175 |
| Fullday Price | 1.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12336001 |
| Held Percent Institutions | 0.12892 |
| Implied Shares Outstanding | 3,983,416 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,769,558,400 |
| Last Split Factor | 1:4 |
| Long Business Summary | Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. |
| Long Name | Revelation Biosciences, Inc. |
| Market | us_market |
| Market Cap | 4,182,586 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_696222591 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -19,201,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,102,918 |
| Number Of Analyst Opinions | 2 |
| Open | 1.04 |
| Operating Cashflow | -9,327,937 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 800 3717 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -1.9047601 |
| Post Market Price | 1.03 |
| Post Market Time | 1,787,961,486 |
| Previous Close | 1.03 |
| Price Eps Current Year | -0.20250723 |
| Price Hint | 4 |
| Price To Book | 0.4076087 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.107 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 1.94175 |
| Regular Market Day High | 1.06 |
| Regular Market Day Low | 1.0001 |
| Regular Market Day Range | 1.0001 - 1.06 |
| Regular Market Open | 1.04 |
| Regular Market Previous Close | 1.03 |
| Regular Market Price | 1.05 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 20,005 |
| Return On Assets | -0.78726995 |
| Return On Equity | -1.5476601 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,983,416 |
| Shares Percent Shares Out | 0.0039 |
| Shares Short | 15,394 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 20,200 |
| Short Name | Revelation Biosciences, Inc. |
| Short Percent Of Float | 0.004 |
| Short Ratio | 0.41 |
| Source Interval | 15 |
| State | CA |
| Symbol | REVB |
| Target High Price | 19.5 |
| Target Low Price | 16.0 |
| Target Mean Price | 17.75 |
| Target Median Price | 17.75 |
| Total Cash | 11,482,792 |
| Total Cash Per Share | 2.883 |
| Total Debt | 739,916 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 27.03 |
| Trailing P E | 0.038845725 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.817535 |
| Two Hundred Day Average Change | -0.7675351 |
| Two Hundred Day Average Change Percent | -0.42229453 |
| Type Disp | Equity |
| Volume | 20,005 |
| Website | https://www.revbiosciences.com |
| Zip | 92,122 |